Exabis Library
Welcome to the e-CCO Library!
P635 Superior outcomes with early biologic-combination treatment in Crohn’s Disease: Data from an international inception cohort
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P635: Assessment of sarcopenia and nutritional status in a cohort of patients with Crohn’s disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P635: Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to infliximab in patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P635: Enteral nutrition in the treatment of young adults with active Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P635: Incidence, prevalence, disease phenotype and maximal therapeutic step in Ulcerative Colitis patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem County cohort
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P635: Real-world treatment persistence and associated costs with biologic therapy in patients with inflammatory bowel disease (IBD): Results of a retrospective cohort analysis of 1,149 patients treated in Germany
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P635: Risankizumab - real world Israeli data in severe refractory IBD patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P636 Changes in peripheral helper T-cell was associated with sustained response to a 12-week EEN therapy in active Crohn’s disease: A pilot study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P636: Impact of anti-TNF treatment on extra-intestinal manifestations in patients with inflammatory bowel disease: real-world data in Germany
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P636: Long-term outcome of anti-tumour necrosis factor treatment in inflammatory bowel disease: A real-life observational study at Østfold Central Hospital, Norway
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P636: Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn's disease: Results from the EVOLVE Expansion study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P636: Reproducibility of the main prognostic factors for postoperative recurrence in a cohort of patients with Crohn's disease under anti-Tnf therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P636: The natural history of COVID-19 in patients with IBD: A nationwide study by the Hellenic Society for the Study of IBD.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P636: Work disability after 20 years with Inflammatory Bowel Disease - results from the IBSEN study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P637 PERFUSE: A french non-interventional cohort study of infliximab-naive and transitioned patients receiving infliximab biosimilar SB2; An interim analysis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P637: Anti-infliximab antibody concentrations guide therapeutic decision-making in patients with Crohn's disease losing clinical response
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P637: High faecal and serum tumour necrosis factor-α levels are associated with non-response to infliximab in patients with ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P637: Incidence rate and clinical outcome of severe COVID-19 in Inflammatory Bowel Disease patients in a population-based setting
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P637: MMP-2 and -8 degraded and citrullinated-vimentin (VICM) correlates to disease activity in inflammatory bowel diseases
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P637: Risks of Development of COVID-19 among Patients with Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM